Gabapentin
Product Images NDC 68071-2458

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68071-2458). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2458 1)

Label for Gabapentin 100 mg capsules by NuCare Pharmaceuticals, Inc. The label states quantity as 100 capsules and includes NDC number 68071-2458-1. It features patient instructions for dosage timing, manufacturer details, and storage instructions at controlled temperature 68-77°F. The product is Rx only and includes barcode and serial numbers.*

FDA Label Image

Figure 1 (Image 01)

A line graph depicting mean pain scores over an 8-week period, comparing gabapentin 3600 mg/day and placebo. The x-axis shows weeks from baseline to week 8, with a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis represents mean pain scores ranging from 0 to 10. Gabapentin shows a decreasing pain score trend, while placebo remains relatively stable.*

FDA Label Image

Figure 2 (Image 02)

Line graph showing mean pain score over 7 weeks comparing placebo with Gabapentin at 1800 mg/day and 2400 mg/day doses. The x-axis represents weeks including a 3-week dose titration period followed by a 4-week fixed dose period; the y-axis shows the mean pain score from 0 to 10. Gabapentin groups show a greater decrease in pain scores compared to placebo.*

FDA Label Image

Figure 3 (Image 03)

A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies,' showing results for Study 1 and Study 2. The vertical axis represents percentage from 0% to 100%. Bars compare placebo (PBO) and Gabapentin (GBP) doses: Study 1 shows PBO at 12% and GBP 3600 mg at 29%, Study 2 shows PBO at 14%, GBP 1800 mg at 32%, and GBP 2400 mg at 34%. Statistical significance is noted with ** p < 0.01 and *** p < 0.001.*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

A formula depicting the calculation for creatinine clearance (CLCr) involving age, weight, serum creatinine, and a gender-specific adjustment factor.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure diagram depicting the molecular arrangement of gabapentin, showing the cyclohexane ring bonded to an amino group and a carboxyl group, corresponding to the active ingredient gabapentin.*

FDA Label Image

Image-09 (Image 09)

A scatter plot showing percentage difference on the y-axis versus daily dose in milligrams on the x-axis for Gabapentin across three studies labeled a, b, and c. Data points illustrate differences at doses of approximately 600, 900, 1200, and 1800 mg with corresponding percentage differences ranging between about 7% and 19%.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.